Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03296137
Other study ID # AA1720
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 13, 2017
Est. completion date September 30, 2020

Study information

Verified date August 2020
Source Herlev Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.


Description:

Adoptive cell therapy (ACT) is a personalized form of immunotherapy, where lymphocytes isolated from the patient's own tumor tissue are expanded 1000-fold ex-vivo and then infused back into the patient. The lymphocytes are then able to recognize and attack remaining cancer cells. This approach has shown remarkable clinical results in several trials conducted worldwide for patients with advanced melanoma - some with durable remissions. Promising clinical results were obtained in smaller trials where patients with disparate solid tumors were treated with tumor-infiltrating lymphocytes (TILs). At Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, there are currently clinical trials undergoing in ovarian and renal cancer, and internationally ACT is being tested in an increasing number of cancer diagnoses, some trials are even recruiting patients across cancer types. Studies have shown that a high intratumoral infiltration with TILs in is correlated to the general clinical outcome of the disease in virtually all solid tumors, and thus clinical trials with TIL-based ACT to different cancer diagnoses have been undertaken.

To support the TIL-mediated tumor elimination, in classical ACT protocols patients go through a highly specialized treatment regime before and after TIL infusion. This regime includes lymphodepletion with 7 days non-myeloablative chemotherapy, to provide an immunological window of opportunity for the infused TILs, and concomitant immune stimulation with interleukin-2 (IL-2). Checkpoint inhibition to support the anti-tumor activity of TILs is currently under extensive investigation in several other trials worldwide. Thus, lymphodepletion and IL-2 stimulation are well-established as supportive therapy and already an integrated part of current ACT protocols and while checkpoint inhibition is a new addition at CCIT; internationally other centers have ongoing comparable trials.

Drug-based immunotherapy in the form of checkpoint inhibitors (anti-PD-1 and anti-CTLA-4) has yielded impressive clinical results across tumor histologies. Recent results indicate that the effect of immunotherapy relies not so much on the cancer diagnoses but rather on the genomic and immunologic features of the individual patient's cancer disease. Both ACT and checkpoint inhibition work by tipping the immunological balance in favor of activation and away from suppression or avoidance by the cancer cells. Scientific evidence now show that administering anti-CTLA-4 and PD-1 could provide a benefit in the ACT setting, and several ongoing clinical trials are testing combinations of ACT and checkpoint inhibition. To synergistically maximize the immunological potential, we wish to combine ACT with an anti-CTLA-4 antibody (Ipilimumab) prior to tumor resection and an anti-PD-1 antibody (Nivolumab) in combination with TIL infusion.

Patients will be treated with one dose of Ipilimumab 14 days before undergoing surgery to harvest tumor material for TIL production. Patients is admitted on day -8 in order to undergo lymphodepleting chemotherapy with cyclophosphamide and fludara starting day -7. On day -2 patients will start treatment with Nivolumab every 2 weeks for a total of 4 doses to increase the activity of the infused TIL product.

Available evidence indicates that ACT is a safe and feasible treatment option in an increasing number of solid tumors, and that it should be tested in all cancer patients regardless of their cancer diagnosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 25
Est. completion date September 30, 2020
Est. primary completion date March 13, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Only patients within the Danish Healthcare system are eligible for enrollment.

Inclusion Criteria:

- Histologically verified metastatic or locally advanced cancer diagnosis

- At least one lesion (>1 cm3) available for surgical resection

- Not candidate for standard treatment options

- Age of 18-70 years

- Performance status of 1 or 0.

- Life expectancy > 6 months

- One or more measurable parameter according to RECIST 1.1.

- No significant toxicity from previous cancer treatments (CTC=1). Except aloplecia (CTC=2) or neuropathy (CTC=2)

- Sufficient organ function, including:

- Absolute neutrophil count (ANC) = 1.500 /µl

- Leucocyte count = normal limit

- Platelets = 100.000 /µl and <700.000 /µl

- Hemoglobin = 6,0 mmol/l (regardless of prior transfusion)

- S-creatinine < 140

- S-bilirubin = 1,5 times upper normal limit

- ASAT/ALAT = 2,5 times upper normal limit

- Alkaline phosphatase = 5 times upper normal limit

- Lactate dehydrogenase (LDH) = 5 times upper normal limit

- Sufficient coagulation: PP-time>40 and INR<1,5

- Women in the fertile age must use effective contraception. This applies from inclusion and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered safe contraceptives.

- Signed statement of consent after receiving oral and written study information

- Willingness to participate in the planned treatment and follow-up and capable of handling toxicities.

Exclusion Criteria:

- A history of prior malignancies. Patients treated for another malignancy can only participate if they are without signs of disease for a minimum of 3 years after last treatment.

- Primary brain tumor or verified brain metastases

- Known hypersensitivity to one of the active drugs or excipients.

- Significant medical conditions, including but not limited to severe asthma/COLD, significant cardiac disease, poorly regulated insulin dependent diabetes mellitus.

- Creatinine clearance below 70 ml/min .

- Acute or chronic infections with HIV, hepatitis, syphilis etc.

- Severe allergies or previous anaphylactic reactions.

- Active autoimmune disease, such as autoimmune neutropenia/thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, Sjögren's syndrome, sclerodermia, myasthenia gravis, goodpastures disease, addison's disease, hashimoto's thyroiditis, graves' disease etc.

- Pregnant women and women who are breastfeeding.

- Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone methotrexate etc.)

- Simultaneous treatment with other experimental drugs.

- Simultaneous treatment with other systemic anti-cancer treatments.

- Patients with active or uncontrollable hypercalcemia.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous tumor-infiltrating lymphocytes
Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
Drug:
Ipilimumab
One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
Nivolumab
4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
proleukin
2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
Cyclophosphamide
2 doses (60 mg/kg) prior to TIL infusion
Fludara
5 doses (25 mg/m2) prior to TIL infusion

Locations

Country Name City State
Denmark Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Inge Marie Svane

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and type of reported adverse events Determine the safety of the administration of TIL therapy including checkpoint inhibitors, lymphodepleting chemotherapy and Interleukin-2 for patients with cancer by reporting adverse events according to CTCAE v. 4.0. Up to 2,5 years from begin of study
Secondary Treatment response, progressive disease Clinical response in progression-free survival to treatment according to RECIST 1.1 Up to 7 years from begin of study
Secondary Treatment response, surival Clinical response in terms of overall survival. Up to 7 years from begin of study
Secondary Treatment related immune response Flow cytometry-based immunological evaluation of peripheral blood 3 years from begin of study
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases